$115.23 Million

IVERIC bio, Inc.

Follow-on Offering

Lead Left Bookrunner, July 2021

IVERIC bio, Inc. is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

More Like This

Jul 2021
$584.78 Million

Follow-on Offering

Bookrunner

View Details
Jun 2021
$257.025 Million

Follow-on Offering

Bookrunner

View Details
May 2021
$388.13 Million
R1 logo

Follow-on Offering

Co-Manager

View Details